Expression of manganese superoxide dismutase in patients with breast cancer  by Tsai, Shih-Meng et al.
Kaohsiung Journal of Medical Sciences (2011) 27, 167e172ava i lab le at www.sc iencedi rec t .com
journa l homepage : ht tp : / /www.k jms-on l ine .comORIGINAL ARTICLE
Expression of manganese superoxide dismutase
in patients with breast cancer
乳癌病人乳房組織錳超氧化物歧化酶表現之研究Shih-Meng Tsai a, Ming-Feng Hou b,c, Szu-Hsien Wu d,e, Bao-Wen Hu f, Sheau-Fang Yang g,
Wan-Tzu Chen g, Chee-Yin Chai g, Hsu Ma d,e, Li-Yu Tsai f,*
蔡世盟 a, 侯明鋒 b,c, 吳思賢 d,e, 胡寶文 f, 楊曉芳 g, 陳婉姿 g, 蔡志仁 g, 馬旭 d,e, 蔡麗玉 f,*aDepartment of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan
bDepartment of Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan
cCancer Center, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
dDivision of Plastic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
eDepartment of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan
f Faculty of Medical Laboratory and Biotechnology Science, College of Health Science, Kaohsiung Medical
University, Kaohsiung, Taiwan
gDepartment of Pathology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan
Received 6 October 2010; accepted 26 November 2010
Available online 21 March 2011KEYWORDS
Breast cancer;
Ductal carcinoma in
situ;
Invasive ductal
carcinoma;
Manganese superoxide
dismutase;
Immunohistochemical
stain* Corresponding author. Faculty of
University, No. 100, Shih-Chuan 1st Ro
E-mail address: tsliyu@kmu.edu.tw
1607-551X/$36 Copyright ª 2011, Else
doi:10.1016/j.kjms.2010.11.003Abstract Breast cancer has become the second leading cancer among females in Taiwan.
Even though the etiology of breast cancer is multifactorial, oxidative stress plays an important
role in the carcinogenesis. The purpose of this study was to investigate the expression of
manganese superoxide dismutase (MnSOD), one of the major antioxidant enzymes that is
involved against oxidative stress, in adjacent cancer-free breast tissues and neoplasm tissues
within the same patient. Sixty-five breast cancer patients’ formalin-fixed tissue blocks,
including ductal carcinoma in situ (DCIS) tissues, invasive ductal carcinoma (IDC) tissues,
and adjacent cancer-free tissues, were evaluated by immunohistochemical stain. Meanwhile,
their demographic and clinical information was also collected. The combined scores of MnSOD-
positive cell proportion and MnSOD staining intensity were compared for different tissues
within the same patient. The results showed that the mean combined scores of MnSOD expres-
sion in adjacent cancer-free tissues (6.33), IDC (5.30), and DCIS (3.78) were significantly
different when assessed by repeated-measurement analysis of variance (FZ 14.17,Medical Laboratory and Biotechnology Science, College of Health Sciences, Kaohsiung Medical
ad, Kaohsiung 807, Taiwan.
(L.-Y. Tsai).
vier Taiwan LLC. All rights reserved.
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乳癌;
乳腺管原位癌;
浸潤性乳腺管癌;
錳超氧化物歧化酶;
免疫組織化學染色p< 0.001). Additionally, the results revealed that the distribution of strong MnSOD protein
expression was 80.0%, 72.3%, and 52.3% in adjacent cancer-free tissues, IDC, and DCIS, respec-
tively. However, there was no statistically significant relationship between the expression of
MnSOD and grades of breast cancer or other clinicopathologic variables. We suggest that the
expression of MnSOD in neoplasm tissues, independent of the clinicopathologic characters,
plays a critical role in breast cancer biology.
摘要乳癌目前已經位居台灣女性癌症的第二位，根據文獻報導，乳癌雖然有許多的致病因子，然
而氧化性傷害在其致癌機轉中扮演重要的角色，因此本研究擬探討生物體中最重要的抗氧化酵
素–錳超氧化物歧化酶(Manganese superoxide dismutase; MnSOD)在乳癌組織中之表現。本實驗
共收集65位診斷為乳癌病人(年紀51.510.7歲)之乳房組織為實驗材料。經由免疫組織化學染色
法分析同一病人之乳腺管原位癌(DCIS)、浸潤性乳腺管癌(IDC) 及其鄰近無癌化乳房組織之MnSOD
蛋白表現。而MnSOD蛋白表現之綜合分數表示方法乃結合細胞染色定性強度及定量評分價數來呈
現。結果顯示：於鄰近之無癌化乳房組織、IDC與DCIS等乳房癌組織之MnSOD蛋白表現之平均綜
合分數分別為6.33、 5.30與3.79。以重複測量變異數分析，發現：這些平均值具有統計上的差異
(FZ 14.17, p< 0.001)。此外，本研究也指出：於同一病人之鄰近無癌化乳房組織、IDC、DCIS
等乳房癌組織其MnSOD蛋白之極強免疫染色反應比例分別為80.0%、 72.3% 和 52.3%。然而在本
研究中也發現MnSOD蛋白表現之平均綜合分數與其他臨床指標值之間均無統計學上的相關性。綜
合以上結果，MnSOD蛋白表現在乳癌致癌過程中可能扮演重要的角色。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Breast cancer is the most frequent cancer in women (22.9%
of all cancers), with an estimated 1,384,155 new cases in
2008 according to the global cancer statistics from the Web
site of The International Agency for Research on Cancer
[1]. Breast cancer is the most prevalent tumor in women in
the West and is the second leading cause of cancer deaths
among females in Taiwan. It is second only to cervical
cancer, and there has been an annual steady increase in
the past 20 years [2,3]. The incidence has rapidly
increased in other areas of Asia in the past decade [3]. The
research of epidemiology in Taiwan indicated that this
increase was more apparent in the younger age groups
rather than the older age groups, and the age-specific
incidence rates peaked between ages 45 years and 49
years [3,4].
The etiology of breast cancer is multifactorial.
Hormonal, genetic, and environmental factors appear to
interplay in the pathogenesis of breast cancer [5]. Increased
lifetime exposure to endogenous or exogenous hormone is
recognized as a major risk factor in the development of
breast cancer [6]. Several genes, for example, BRAC1,
BRAC2, HER-2/neu, and p53, are linked to breast cancer
susceptibility and development [7,8]. In our previous
research, it was demonstrated that overexpression of the
HER-2/neu gene might induce nuclear factor-kappaB
activity in human breast cancer cells [9]. Reactive oxygen
species (ROS) are byproducts generated endogenously by all
aerobic cells as the result of oxygen metabolism. High
concentrations of ROS, which are highly reactive, exert
harmful effects on living organisms, inducing oxidative
damage to their DNA and cell membranes. Numerous reports
have implicated the association of free-radical generation
with the pathogenesis of a wide variety of diseases [10e16].
The accumulation of DNA damages is believed to contribute
to carcinogenesis [17].Superoxide dismutases (SODs) decompose superoxide
radicals to hydrogen peroxide, and then hydrogen peroxide
and other peroxides of the cell are consumed by multiple
enzymes, such as catalase and glutathione peroxidase [17].
There are three kinds of SODs in human tissues; manganese
SOD (MnSOD) in the mitochondria, copper/zinc-superoxide
dismutase (CuZnSOD) in the cytosol, and extracellular SOD
in the extracellular matrix [18]. MnSOD is considered to be
one of the most important antioxidant enzymes that acts
against endogenous and exogenous superoxide radicals [19].
The basal expression of MnSOD is usually low, almost unde-
tectable, but the enzyme is induced by hyperoxia; irradia-
tion; cytokines, such as tumor necrosis factors, interleukins,
and interferon; and changes in the cellular redox state [20].
Several studies have suggested that the level of MnSOD
in tumor cells is low [21]. Furthermore, MnSOD activity has
been shown to correlate with the degree of differentiation
of nonmalignant and malignant cells, which suggested that
more differentiated cells, such as the normal cells, have
higher MnSOD activity [21,22]. To evaluate the role of
MnSOD in malignancy, we investigated the expression of
MnSOD in invasive and in situ breast carcinomas and
compared the reactivity with that of cancer-free breast
tissues. We would like to find out if there are any corre-
lations between the expressions of MnSOD and sex
hormones [estrogen receptor (ER) and progesterone
receptor (PR)] using the immunohistochemical (IHC) assay
in the studies.
MethodsPatients and study materials
Sixty-five newly diagnosed breast cancer patients (age,
51.5 10.7 years) from Kaohsiung Medical University
Hospital were recruited according to the criterion stating
Table 1 Demographic and clinical characteristics of
patients with breast ductal carcinoma (nZ65)
Parametersa n (%)
Ages, yr 51.5 10.6
Menopausal statuses
Premenopausal 38 (58.5)
Postmenopausal 27 (41.5)
Cancer sites
Left breast 36 (55.4)
Right breast 29 (44.6)
Tumor sizes, cm
<2 28 (46.0)
2e5 26 (42.6)
>5 7 (11.4)
Axillary node involvement
No 34 (52.3)
Yes 31 (47.7)
Histological grades
I 8 (12.3)
II 40 (61.5)
III 17 (26.2)
HER-2/neu
Positive 29 (44.6)
Negative 36 (55.4)
Estrogen receptor
Positive 38 (58.5)
Negative 27 (41.5)
Progesterone receptor
Positive 37 (56.9)
Negative 28 (43.1)
a All of the variables listed were not statistically related to
the expression of manganese superoxide dismutase in invasive
ductal carcinoma.
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and gave their approvals to be the study subjects in this
study. The information about the clinical features, such as
age, menopausal status, tumor size, and others, and the
pathological profiles, including HER-2/neu, ER, and PR
status, was obtained from Kaohsiung Medical University
Hospital medical records for analysis. The detailed
descriptive statistics for those variables were listed in
Table 1.
All the breast tissues, including the breast cancer
tissues and the adjacent cancer-free tissues, after the
surgery had been fixed in 10% buffered formalin and
embedded in paraffin wax before the IHC assay. The
hematoxylin and eosinestained sections from each tumor
sample were examined by an experienced pathologist to
confirm histological diagnosis and to assess tumor content.
However, if the DCIS component was hardly examined in
the collected breast cancer tissues, the collected tissues
would be excluded from this study. This study was
approved by the Ethics Committee of Kaohsiung Medical
University Hospital.IHC staining
A polyclonal rabbit antibody for human MnSOD was used for
the IHC stain. Sections of 3 mm were cut from appropriately
selected paraffin blocks containing the breast tissues.
These were mounted on glass slides coated with ploy-L-
lysine and dried overnight at 60C. The sections were
deparaffinized in xylene and rehydrated by a series of
graded alcohols. To enhance immunoreactivity, the
sections were incubated in a 0.1 M citrate buffer (pH 6.0)
and autoclave-treated at 121C for 10 minutes. Endogenous
peroxidase activity was blocked by incubation in 3%
hydrogen peroxide for 5 minutes at room temperature.
After being washed with Tris buffer solution (TBS) and
incubation with 5% bovine serum albumin, the sections
were incubated with rabbit polyclonal primary antibody
MnSOD (06-984, 1:50; Upstate Biotechnology, Charlottes-
ville, VA, Virginia, USA) for 1 hour at room temperature.
The sections were rinsed off with TBS at pH 7.6 and incu-
bated with the linking biotinylated antibody (DAKO LSAB2
kit, K0675; DAKO Glostrup, Denmark) for 20 minutes.
Subsequently, the sections were rinsed off with TBS fol-
lowed by incubation with the peroxidase-conjugated
streptavidin complex (DAKO LSAB2 kit, K0675) for 20
minutes. Freshly prepared 3, 3’-diaminobenzidine tetra-
hydrochloride (DAB) solution (Sigma K3468, St. Louis, USA)
was applied on the slides for 5 minutes after it had been
rinsed off with TBS. DAB was removed by rinsing with
distilled water. The slides were counterstained with
hematoxylin, dehydrated in increasing grades of ethanol,
and cleared in xylene. The negative controls were obtained
by replacing the primary antibody with nonimmune serum.
Even though the pathological profiles, including ER, PR,
and HER-2/neu, were all obtained from the patients’
medical records, the methods for such assessments will be
illustrated briefly. The IHC stain method of ER, PR, and Her-
2/neu was the same as that of MnSOD. The concentration
of the primary anti-ER antibody, anti-PR antibody, and
anti-HER-2/neu were 1:50 (DAKO, DAKO, and Biogenex
(San Francisco, USA), respectively). The positive criterion
for ER and PR is greater than 10% tumor cells with nuclear
staining, and the positive criterion for HER-2/neu is uniform
intense membranous staining in at least 30% of cells.
The IHC stainofMnSODexpressionwasevaluatedas follows
[20]: (1) The qualitative intensity of the IHC stain with all the
antibodies was evaluated by dividing the staining reactions
into four groups: 1Zweak cytoplasmic staining intensity, less
than 25% of the intensity of histiocytes; 2Zmoderate cyto-
plasmic staining intensity, 25e50% of the intensity of histio-
cytes; 3Z strong cytoplasmic staining intensity, 50e75% of
the intensity of histiocytes; 4Z very strong cytoplasmic
staining intensity, 75e100% of the intensity of histiocytes. (2)
The quantity of the IHC stain was divided into five groups
according to the staining reactions: 0Z no positive immu-
nostaining; 1Z less than 25% of tumor cells showing cyto-
plasmic positivity; 2Z 25e50% of tumor cells showing
cytoplasmic positivity; 3Z 50e75% of tumor cells showing
cytoplasmic positivity; 4Z greater than 75% of tumor cells
showing cytoplasmic positivity. (3) A combined score for the
IHC staining, based on both qualitative and quantitative IHC
staining,was adopted in this study. The combined scoreswere
170 S.-M. Tsai et al.then divided into four main groups: xZ no immunostaining,
score 0; þZweak immunostaining, scores 1e2;
þþZmoderate immunostaining, scores 3e4;þþþZ strong
immunostaining, scores 5e8. Toobtainmoreobjective scores,
two pathologists (also the coauthors of this study) who were
blinded to the clinical outcomeevaluated the immunostaining
patterns independently. If a discrepancy was present, the
pathologists reanalyzed the slides together and reached
a consensus regarding the final score.
Statistical analysis
SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. The expression of MnSOD in the invasive
carcinomas, in situ carcinomas, and adjacent cancer-free
epithelium cells was evaluated by repeated-measurement
analysis of variance (ANOVA). The associations between the
expression of MnSOD and those of binary variables and
nominal variables in the patients with breast cancer were
evaluated by Student t test and ANOVA, respectively. The
probability p value less than 0.05 was considered statisti-
cally significant.
Results
There were 65 women with newly diagnosed breast cancer
in this research, ranging in ages from 28 years to 83 years,
with a mean age of 51.5 years. General characteristics of
the study subjects were presented in Table 1, including the
distribution frequencies of their menopausal statuses and
clinical manifestations, such as histological grades, cancer
sites, tumor sizes, involvement of axillary nodes, and the
pathological profiles, including the statuses of HER-2/neu,
ER, and PR. The distribution frequency of the post-
menopausal status was 59%. Our analyses revealed the
following: higher proportions of tumors in the left breast
(55%), tumor size less than 2 cm (46.0%), no axillary node
involvement (52.3%), Grade II tumors (62%), negative HER-
2/neu status (55%), and positive ER (59%) and PR statuses
(57%). However, all of the aforementioned variables did not
significantly correlate with the combined scores of MnSOD
expression in invasive carcinoma tissues assessed by
Student t test or ANOVA. Moreover, the p value for tumor
sizes, axillary node involvement, histogrades, and statuses
of Her-2/neu, ER, and PR, were 0.23, 0.34, 0.06, 0.20, 0.34,
and 0.75, respectively. Even though the p value forFigure 1. Manganese superoxide dismutase staining: (A) adjac
(400), and (C) in situ carcinoma tissue (400) of the same patienhistograde statuses is close to a significant level, we believe
that the results of the MnSOD expression in different tissues
and the aim of this research could not be biased by the
aforementioned variables.
Regarding MnSOD expression, we found that the immu-
noreactivity of MnSOD was stronger in the adjacent cancer-
free epithelium cells than in the breast cancer cells
(Fig. 1A). Because of the inflammatory cells and fibroblastic
cells of the desmoplastic stroma surrounding the tumor
cells as well as tissue histiocytes and endothelial cells,
a relatively strong immunoreactivity was observed. As
a result, we also noticed that the cytoplasmic immunos-
taining of MnSOD expressed around the invasive lesions
(Fig. 1B) and the in situ lesions (Fig. 1C). The quantities of
the MnSOD immunoreactivity in invasive carcinoma, in situ
breast lesions, and the adjacent cancer-free tissues are
shown in Table 2. The frequencies of strong MnSOD protein
expression were 80.0%, 72.3% and 52.3% in the adjacent
cancer-free tissues, invasive carcinomas tissues, and in situ
carcinomas tissues, respectively. Furthermore, the mean
combined scores were 6.33, 5.30, and 3.79, in the adjacent
cancer-free tissues, invasive carcinoma tissues, and in situ
carcinoma tissues, respectively; they differed significantly
from each other when assessed by repeated-measurement
ANOVA (FZ 14.17, p< 0.001).Discussion
Tumorigenesis is a multistep process that requires the
acquisition of certain properties common to all tumors [23].
The increasing incidence of breast cancer urges people the
need to understand the various mechanisms involved in
breast tumorigenesis. Oxidative DNA damage, including
mutagenic and cytotoxic lesions, is implicated in the initia-
tion phase of carcinogenesis. The interaction between
oxygen radicals and DNA produces base adducts, deletions,
frameshifts, strand breaks, and DNAeprotein crosslinks [24].
Oxygen free radicals also attack breast epithelium and lead
to fibroblast proliferation, epithelial hyperplasia, cellular
atypia, and breast cancer [25]. Biologically, a living body has
to develop an efficient protection against harmful effects of
ROS by both enzymatic and nonenzymatic antioxidant
mechanisms. SOD, the most important antioxidant enzyme,
catalyzes the dismutation of highly reactive O2
． to O2 and
H2O2, a less ROS. In the human body, MnSOD was responsible
for the detoxification of ROS in the mitochondria [26], whichent cancer-free tissue (400), (B) invasive carcinoma tissue
t with breast ductal carcinoma.
Table 2 Manganese superoxide dismutase immunoreactivity in the invasive carcinomas, the in situ carcinomas, and the
adjacent cancer-free tissues of the same patient with breast ductal carcinoma
Sites Frequencies for expression Combined scorea
Negative Weak Moderate Strong
n (%) n (%) n (%) n (%) Mean SD
Invasive carcinoma 7 (10.8) 1 (1.5) 10 (15.4) 47 (72.3) 5.30 5.76
In situ carcinoma 26 (40.0) 1 (1.5) 4 (6.2) 34 (52.3) 3.79 11.47
Cancer-free tissue 10 (15.4) 1 (1.5) 2 (3.1) 52 (80.0) 6.33 8.47
a There were significant differences in the means among these tissues when assessed by repeated-measurement analysis of variance
(FZ 14.17, p< 0.001).
SDZ standard deviation.
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However, epidemiologically, the role of MnSOD was ambig-
uous in cancer research. Mokenge Malafa et al. [27] showed
that MnSOD expression, which was evaluated by Western
blot analysis, was upregulated in the primary tumors of
gastric cancer patients with lymph node metastases and in
lung carcinomas [28]. In contrast, MnSOD levels [29] and
MnSOD immunoreactive protein [30] have been found to be
decreased in human pancreatic cells from chronic pancrea-
titis specimens when compared with those in normal
pancreas. Other types of cancers, including gastric tumor
[31,32] and prostatic cancer [32], also showed the same
consequences. In breast cancer research regarding the
enzymatic activities of SOD, R. Kumaraguruparan et al. [33]
suggested that upregulation of antioxidants induced by
oxidative stress confers a selective growth advantage to
tumor cells over their adjacent normal counterparts.
Conversely, a significant decrease in the activities of SOD of
erythrocyte lysate in breast cancer patients as compared
with those of the control subjects and fibroadenomapatients
was reported in another study [34]. Our previous research
revealed that the activities of antioxidant enzymes in the
blood of the patients with breast cancer were significantly
higher than those of the controls [35].
To clarify the role of MnSOD, Li et al. [36] proposed that
the activity of MnSOD correlated with the degree of
differentiation in human breast cancer cells. Portakal et al.
pointed out that activities of MnSOD and the total SOD
enzymes in breast tumor tissues were significantly higher
than those in the corresponding cancer-free tissues [37].
Other evidences revealed by Liu and Zhong et al. showed
that activities of MnSOD and total SOD were increased in
human tumor cell lines [38,39], and Soini et al. [20] pointed
out that MnSOD expression assayed by IHC was less frequent
in invasive breast carcinomas than in in situ carcinomas or
nonneoplastic breast epithelial cells. In the present study,
we investigated the expression of MnSOD by IHC in invasive
breast carcinomas, in situ carcinomas, and in adjacent
cancer-free tissues with a unique statistical method,
repeated-measurement ANOVA, which was not adopted in
previous studies, highlighting the within-subject differ-
ence. Therefore, it is hard to elucidate the results of this
study compared with other previous studies. However, the
results showed that the expression of MnSOD was decreased
in the in situ carcinoma tumor tissues in comparison with
that in the invasive carcinoma or the adjacent cancer-free
tissues, which could be explained as follows. First, MnSODmight act as a tumor suppressor in normal condition; thus,
MnSOD might protect the normal tissues from the attack of
free radical damages. Second, lower expression of MnSOD
enhanced the development of tumorogenesis; as a result,
the expression of MnSOD was decreased in the in situ
carcinoma. Finally, the expression of MnSOD was increased
in the invasive carcinoma to help tumors infringe the
surrounding cells. Hence, the expression of MnSOD was
higher in invasive carcinoma than in in situ carcinoma.
Based on the evidence revealed by this present study, we
deem that H2O2 could be the key point to explain why there
was a higher expression of MnSOD in breast cancer tissues
than in in situ carcinoma tissues. H2O2 was generated with
the help of MnSOD, which has a special property to pene-
trate cell membranes freely, and could attack the
surrounding normal cells and then help cancer cell invasion.
Taken together, we propose that the expression of MnSOD
protein in neoplasm tissues, independent of the tumor
grade or stage, plays a critical role in breast cancer biology.Acknowledgments
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